TRYP Therapeutics

Hiring

A public company • CSE: TRYP

La Jolla, California, USA

https://www.tryptherapeutics.com

Development Psilocybin Research

EGB Ventures

Bordeaux Capital

James Kuo

CEO & Director

Jay Campbell

CBO

Terese Gieselman

CFO

Tom D'Orazio

VP of Operations

Larry Norder

VP of Manufacturing

William Garner

Executive Chairman

Gage Jull

Director

Peter Molloy

Director

James Gilligan

Chief Executive Officer

Director, Investor Relations (Psychedelics)

San Diego, California, USA

Full Time

Jun 04, 2021

Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

Active, not recruiting

Binge Eating Disorder

Start Date: Mar 2022

Last Updated: Jan 2023

Gainesville, Florida, USA

Psilocybin

Open-label Study to Assess the Safety and Efficacy of TRP-8802 With Psychotherapy in Adult Participants With Fibromyalgia

Not yet recruiting

Fibromyalgia

Start Date: Mar 2022

Last Updated: Nov 2021

Ann Arbor, Michigan, USA

Psilocybin

Bioavailability Study of Psilocybin in Normal Adults

Withdrawn

Healthy

Start Date: Jun 2023

Last Updated: May 2023

Psilocybin

Related Organizations:

Beckley Psytech

MagicMed Industries

IntelGenx

Magical Brands

M2BIO

BioPharm

TRYP Therapeutics

Investors

People

Jobs

Clinical Trials

Related Organizations: